| pubmed-article:20621728 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20621728 | lifeskim:mentions | umls-concept:C0034325 | lld:lifeskim |
| pubmed-article:20621728 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:20621728 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:20621728 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:20621728 | lifeskim:mentions | umls-concept:C2347168 | lld:lifeskim |
| pubmed-article:20621728 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:20621728 | pubmed:issue | 14 | lld:pubmed |
| pubmed-article:20621728 | pubmed:dateCreated | 2010-7-12 | lld:pubmed |
| pubmed-article:20621728 | pubmed:abstractText | A novel series of pyrrole inhibitors of MEK kinase has been developed using structure-based drug design. Optimization of the series led to the identification of potent inhibitors with good pharmaceutical properties. | lld:pubmed |
| pubmed-article:20621728 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20621728 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20621728 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20621728 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20621728 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20621728 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20621728 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20621728 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:20621728 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:20621728 | pubmed:author | pubmed-author:AdamsMark EME | lld:pubmed |
| pubmed-article:20621728 | pubmed:author | pubmed-author:MolClifford... | lld:pubmed |
| pubmed-article:20621728 | pubmed:author | pubmed-author:DongQingQ | lld:pubmed |
| pubmed-article:20621728 | pubmed:author | pubmed-author:WallaceMichae... | lld:pubmed |
| pubmed-article:20621728 | pubmed:author | pubmed-author:DouganDouglas... | lld:pubmed |
| pubmed-article:20621728 | pubmed:author | pubmed-author:ShiLihongL | lld:pubmed |
| pubmed-article:20621728 | pubmed:author | pubmed-author:FeherVictoria... | lld:pubmed |
| pubmed-article:20621728 | pubmed:author | pubmed-author:KanouniToufik... | lld:pubmed |
| pubmed-article:20621728 | pubmed:author | pubmed-author:O'ConnellShaw... | lld:pubmed |
| pubmed-article:20621728 | pubmed:author | pubmed-author:HalkowyczPetr... | lld:pubmed |
| pubmed-article:20621728 | pubmed:copyrightInfo | 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20621728 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20621728 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:20621728 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:20621728 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20621728 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20621728 | pubmed:pagination | 4156-8 | lld:pubmed |
| pubmed-article:20621728 | pubmed:meshHeading | pubmed-meshheading:20621728... | lld:pubmed |
| pubmed-article:20621728 | pubmed:meshHeading | pubmed-meshheading:20621728... | lld:pubmed |
| pubmed-article:20621728 | pubmed:meshHeading | pubmed-meshheading:20621728... | lld:pubmed |
| pubmed-article:20621728 | pubmed:meshHeading | pubmed-meshheading:20621728... | lld:pubmed |
| pubmed-article:20621728 | pubmed:meshHeading | pubmed-meshheading:20621728... | lld:pubmed |
| pubmed-article:20621728 | pubmed:meshHeading | pubmed-meshheading:20621728... | lld:pubmed |
| pubmed-article:20621728 | pubmed:meshHeading | pubmed-meshheading:20621728... | lld:pubmed |
| pubmed-article:20621728 | pubmed:meshHeading | pubmed-meshheading:20621728... | lld:pubmed |
| pubmed-article:20621728 | pubmed:meshHeading | pubmed-meshheading:20621728... | lld:pubmed |
| pubmed-article:20621728 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20621728 | pubmed:articleTitle | Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors. | lld:pubmed |
| pubmed-article:20621728 | pubmed:affiliation | Takeda San Diego, 10410 Science Center Drive, San Diego, CA 92121, United States. michael.wallace@takedasd.com | lld:pubmed |
| pubmed-article:20621728 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20621728 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:20621728 | lld:chembl |
